[Functional dyspepsia: approaches to Helicobacter pylori eradication therapy].

Leber, Magen, Darm Pub Date : 1995-05-01
A L Blum, C Kreiss, D Armstrong
{"title":"[Functional dyspepsia: approaches to Helicobacter pylori eradication therapy].","authors":"A L Blum,&nbsp;C Kreiss,&nbsp;D Armstrong","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>At the present, Helicobacter-associated gastritis is not considered to be an important cause of dyspeptic symptoms. Therefore, patients with dyspeptic symptoms and proven Helicobacter-gastritis are diagnosed as having functional dyspepsia, provided that Helicobacter-associated lesions like ulcers or malignancies are absent. It is controversial whether or not to treat a patient with functional dyspepsia with Helicobacter gastritis. Conclusive controlled clinical trials are lacking. If it is assumed in a given patient, that Helicobacter could be responsible for the complaints (an assumption which can never be proven and only suspected when the patient remains asymptomatic during longterm follow-up after cure of the infection) and if the patient has not responded to a standard treatment (antisecretory or prokinetic agents), we recommend Helicobacter therapy. Presently, in spring 1995, the following treatment is, in our view, the best choice during seven (to ten) days: The patient takes 20 mg omeprazol in the morning, 250 mg clarithromycin in the morning and in the evening and 500 mg metronidazole in the morning and in the evening.</p>","PeriodicalId":17969,"journal":{"name":"Leber, Magen, Darm","volume":"25 3","pages":"112-6, 119-20"},"PeriodicalIF":0.0000,"publicationDate":"1995-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leber, Magen, Darm","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

At the present, Helicobacter-associated gastritis is not considered to be an important cause of dyspeptic symptoms. Therefore, patients with dyspeptic symptoms and proven Helicobacter-gastritis are diagnosed as having functional dyspepsia, provided that Helicobacter-associated lesions like ulcers or malignancies are absent. It is controversial whether or not to treat a patient with functional dyspepsia with Helicobacter gastritis. Conclusive controlled clinical trials are lacking. If it is assumed in a given patient, that Helicobacter could be responsible for the complaints (an assumption which can never be proven and only suspected when the patient remains asymptomatic during longterm follow-up after cure of the infection) and if the patient has not responded to a standard treatment (antisecretory or prokinetic agents), we recommend Helicobacter therapy. Presently, in spring 1995, the following treatment is, in our view, the best choice during seven (to ten) days: The patient takes 20 mg omeprazol in the morning, 250 mg clarithromycin in the morning and in the evening and 500 mg metronidazole in the morning and in the evening.

[功能性消化不良:幽门螺杆菌根除治疗方法]。
目前,幽门螺杆菌相关性胃炎并不被认为是消化不良症状的重要原因。因此,有消化不良症状并证实有幽门螺杆菌性胃炎的患者,只要没有幽门螺杆菌相关病变,如溃疡或恶性肿瘤,即可诊断为功能性消化不良。功能性消化不良合并幽门螺杆菌胃炎患者是否治疗存在争议。缺乏结论性的对照临床试验。如果假设在特定患者中,幽门螺杆菌可能是导致这些症状的原因(这种假设永远无法证实,只有当患者在感染治愈后的长期随访中仍无症状时才会怀疑),并且如果患者对标准治疗(抗分泌或促动力药物)没有反应,我们建议使用幽门螺杆菌治疗。目前,在1995年春季,我们认为7(10)天的最佳治疗方案是:患者早上服用奥美拉唑20毫克,早上和晚上服用克拉霉素250毫克,早上和晚上服用甲硝唑500毫克。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信